After a tough year for stock performance in 2021, we lay out why the psychedelic drug industry is poised to bounce back strongly in 2022.
TSI EDITOR |
2022-01-04
MINDCURE moves an important step closer to the full commercial deployment of its iSTRYM digital therapeutics platform, and also makes a key addition to its management team.
TSI EDITOR |
2021-12-17
HIPAA compliance certification is the next step for the Company in working towards having the iSTRYM technology platform classified a ‘Software as a Medical Device’ by the FDA.
TSI EDITOR |
2021-12-16
Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) announces the appointment of Doron Sagman, MD, FRCPC, as the Company’s new Chief Medical Officer (“CMO”)
TSI EDITOR |
2021-12-14
MINDCURE's iSTRYM digital therapeutics platform is a first-mover in supplying this critical IT to mental health treatment. But that's only the beginning of its potential.
TSI EDITOR |
2021-12-08
Psychedelic stocks have recently been punished by the market. The flip-side is that many well-capitalized companies now offer spectacular value propositions.
TSI EDITOR |
2021-12-03
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now